Breast Cancer Clinical Trial

PF-3512676 (CPG 7909) Injection For Patients Who Completed An Oncology Study Using PF-3512676 (CPG 7909)

Summary

This protocol allows patients who completed Coley oncology studies using PF-3512676 (CPG 7909) Injection to continue receiving the treatment until disease progression.

View Eligibility Criteria

Eligibility Criteria

Inclusion Criteria:

Immediate (within 4 weeks) prior completion of a clinical trial of PF-3512676 Injection alone or in combination with other anti-neoplastic treatment for malignancy.

Exclusion Criteria:

The patient has received any anti-neoplastic therapy since completing a prior trial with PF-3512676 Injection, or has participated in another clinical trial following participation in a trial with PF-3512676 Injection.

Study is for people with:

Breast Cancer

Phase:

Phase 2

Estimated Enrollment:

31

Study ID:

NCT00043368

Recruitment Status:

Completed

Sponsor:

Pfizer

Check Your Eligibility

Let’s see if you might be eligible for this study.

What is your age and gender ?

Submit

There are 30 Locations for this study

See Locations Near You

Pfizer Investigational Site
Berkely California, 94704, United States
Pfizer Investigational Site
Gilroy California, 95020, United States
Pfizer Investigational Site
Hollister California, 95023, United States
Pfizer Investigational Site
Los Angeles California, 90057, United States
Pfizer Investigational Site
Los Angeles California, 91342, United States
Pfizer Investigational Site
Palm Springs California, 92262, United States
Pfizer Investigational Site
Stanford California, 94305, United States
Pfizer Investigational Site
New Haven Connecticut, 06504, United States
Pfizer Investigational Site
Bonita Springs Florida, 34135, United States
Pfizer Investigational Site
Bradenton Florida, 34209, United States
Pfizer Investigational Site
Cape Coral Florida, 33990, United States
Pfizer Investigational Site
Fort Myers Florida, 33901, United States
Pfizer Investigational Site
Fort Myers Florida, , United States
Pfizer Investigational Site
Naples Florida, 34102, United States
Pfizer Investigational Site
Plantation Florida, 33324, United States
Pfizer Investigational Site
Port Charlotte Florida, 33980, United States
Pfizer Investigational Site
Sarasota Florida, 34232, United States
Pfizer Investigational Site
Venice Florida, 34285, United States
Pfizer Investigational Site
Venice Florida, 34292, United States
Pfizer Investigational Site
Chicago Illinois, 60611, United States
Pfizer Investigational Site
Chicago Illinois, 60611, United States
Pfizer Investigational Site
Vincennes Indiana, 47591, United States
Pfizer Investigational Site
Ann Arbor Michigan, 48109, United States
Pfizer Investigational Site
Olive Branch Mississippi, 38654, United States
Pfizer Investigational Site
Oxford Mississippi, 38655, United States
Pfizer Investigational Site
Livingston New Jersey, 07039, United States
Pfizer Investigational Site
Asheville North Carolina, 28801, United States
Pfizer Investigational Site
Portland Oregon, 97213, United States
Pfizer Investigational Site
Collierville Tennessee, 38107, United States
Pfizer Investigational Site
Memphis Tennessee, 38017, United States
Pfizer Investigational Site
Memphis Tennessee, 38104, United States
Pfizer Investigational Site
Koeln , 50931, Germany

How clear is this clinincal trial information?

Study is for people with:

Breast Cancer

Phase:

Phase 2

Estimated Enrollment:

31

Study ID:

NCT00043368

Recruitment Status:

Completed

Sponsor:


Pfizer

How clear is this clinincal trial information?

×

Introducing, the Journey Bar

Use this bar to access information about the steps in your cancer journey.

Please confirm you are a US based health care provider:

Yes, I am a health care Provider No, I am not a health care provider